Use of inactivated Escherichia coli enterotoxins to enhance respiratory mucosal adjuvanticity during vaccination in swine

Clinical and Vaccine Immunology

Volumn 18, Issue 11, 2011, Pages 1996-1998

  Barrette, Roger W ^a,b   Szczepanek, Steven M ^a,b   Rood, Debra ^a   Challa, Sreerupa ^a,d   Avery, Naomi ^a   Vajdy, Michael ^c,e   Kramer, Ed ^b   Rodriguez, Luis ^b   Silbart, Lawrence K ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b PLUM ISLAND ANIMAL DISEASE CENTER   (United States)

^c Novartis Vaccines and Diagnostics Inc   (United States)

^d TUFTS UNIVERSITY   (United States)

^e EpitoGenesis Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; ESCHERICHIA COLI ENTEROTOXIN LTK63; ESCHERICHIA COLI ENTEROTOXIN LTR72; FOOT AND MOUTH DISEASE VACCINE; UNCLASSIFIED DRUG;

ANTIBODY TITER; ARTICLE; CPG ISLAND; DRUG EFFICACY; DRUG SAFETY; FOOT AND MOUTH DISEASE; HUMORAL IMMUNITY; IMMUNE RESPONSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; RECOMMENDED DRUG DOSE; TREATMENT RESPONSE; VIRUS TITRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BACTERIAL TOXINS; BLOOD; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; SWINE; TOXOIDS; VACCINATION; VIRAL VACCINES;

EID: 80455128989     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05273-11     Document Type: Article

References (11)

1. Bailey, M., and K. Haverson. 2006. The postnatal development of the mucosal immune system and mucosal tolerance in domestic animals. Vet. Res. 37:443-453. (Pubitemid 43725030)
2. Barrette, R. W., J. Urbonas, and L. K. Silbart. 2006. Quantifying specific antibody concentrations by enzyme-linked immunosorbent assay using slope correction. Clin. Vaccine Immunol. 13:802-805.
3. Fischer, S., et al. 2009. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J. Drug Target. 17:652-661.
4. Gerdts, V., G. K. Mutwiri, S. K. Tikoo, and L. A. Babiuk. 2006. Mucosal delivery of vaccines in domestic animals. Vet. Res. 37:487-510. (Pubitemid 43725033)
5. Giuliani, M. M., et al. 1998. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J. Exp. Med. 187:1123-1132. (Pubitemid 28176412)
6. Liang, S., and G. Hajishengallis. 2010. Heat-labile enterotoxins as adjuvants or anti-inflammatory agents. Immunol. Invest. 39:449-467.
7. Nauwyncy, H. J., G. G. Labarque, and M. B. Pensaert. 1999. Efficacy of an intranasal immunization with gEgC and gEgI double-deletion mutants of Aujeszky's disease virus in maternally immune pigs and the effects of a successive intramuscular booster with commercial vaccines. J. Vet. Med. B 43:713-722.
8. Partidos, C. D., M. Pizza, R. Rappuoli, and M. W. Steward. 1996. The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide. Immunology 89:483-487. (Pubitemid 26419646)
9. Rowlands, D., et al. 1994. The structure of an immunodominant loop on foot and mouth disease virus, serotype O1, determined under reducing conditions. Arch. Virol. Suppl. 9:51-58.
10. Singh, M., M. Briones, and D. T. O'Hagan. 2001. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J. Control Release 70:267-276. (Pubitemid 32155450)
11. Wu, K. Y., et al. 2006. A novel chitosan CpG nanoparticle regulates cellular and humoral immunity of mice. Biomed. Environ. Sci. 19:87-95.